RhumbLine Advisers’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-20,819
| Closed | -$25.2K | – | 4194 |
|
|
2024
Q2 | $25.2K | Sell |
20,819
-39,677
| -66% | -$48K | ﹤0.01% | 3828 |
|
|
2024
Q1 | $142K | Buy |
60,496
+13,381
| +28% | +$31.4K | ﹤0.01% | 3325 |
|
|
2023
Q4 | $89K | Buy |
47,115
+657
| +1% | +$1.24K | ﹤0.01% | 3487 |
|
|
2023
Q3 | $63.6K | Sell |
46,458
-563
| -1% | -$771 | ﹤0.01% | 3591 |
|
|
2023
Q2 | $114K | Sell |
47,021
-597
| -1% | -$1.45K | ﹤0.01% | 3469 |
|
|
2023
Q1 | $274K | Buy |
47,618
+2,243
| +5% | +$12.9K | ﹤0.01% | 2643 |
|
|
2022
Q4 | $406K | Buy |
45,375
+2,606
| +6% | +$23.3K | ﹤0.01% | 2561 |
|
|
2022
Q3 | $608K | Buy |
42,769
+2,768
| +7% | +$39.4K | ﹤0.01% | 2406 |
|
|
2022
Q2 | $584K | Buy |
40,001
+8,322
| +26% | +$121K | ﹤0.01% | 2410 |
|
|
2022
Q1 | $633K | Buy |
31,679
+9,160
| +41% | +$183K | ﹤0.01% | 2312 |
|
|
2021
Q4 | $394K | Buy |
22,519
+1,703
| +8% | +$29.8K | ﹤0.01% | 2604 |
|
|
2021
Q3 | $163K | Buy |
20,816
+563
| +3% | +$4.41K | ﹤0.01% | 2940 |
|
|
2021
Q2 | $208K | Buy |
+20,253
| New | +$208K | ﹤0.01% | 2916 |
|
|
2020
Q2 | – | Sell |
-2,818
| Closed | -$20K | – | 3056 |
|
|
2020
Q1 | $20K | Hold |
2,818
| – | – | ﹤0.01% | 2904 |
|
|
2019
Q4 | $29K | Buy |
2,818
+32
| +1% | +$329 | ﹤0.01% | 2932 |
|
|
2019
Q3 | $172K | Buy |
2,786
+308
| +12% | +$19K | ﹤0.01% | 2783 |
|
|
2019
Q2 | $177K | Buy |
2,478
+1,031
| +71% | +$73.6K | ﹤0.01% | 2825 |
|
|
2019
Q1 | $69K | Buy |
+1,447
| New | +$69K | ﹤0.01% | 2899 |
|